For many years, rare diseases have been a research focus of JARA-BRAIN member Prof. Jörg B. Schulz. Now the physician is also involved in the project "Collaboration on Rare Diseases (CORD)", which is funded by the German Federal Ministry of Education and Research with several million euros as part of the Medical Informatics Initiative. The new project offers the opportunity to collaborate across disciplines with numerous partners in this field to improve the quality of life of patients with rare diseases.
Germany has long been among the world leaders in the race to develop a quantum computer. As part of the BMBF-funded QUASAR project, top-class research institutions, universities and companies now aim to jointly apply the results into practice. The goal is a semiconductor quantum processor made in Germany that is based on the "shuttling" of electrons and is to be achieved with technology available in Germany. Project coordinator is Prof. Hendrik Bluhm, director at the JARA Institute for Quantum Information.
A team around JARA-FIT member Prof. Stefan Tautz, together with colleagues from Marburg and Graz, has acquired electron orbital images with extremely high time resolution to track electrons in a chemical reaction in time and space. The investigations of the international research team not only contribute to the fundamental understanding of chemical reactions and electron transfer processes, but also open up future perspectives for the optimization of interfaces and nanostructures. The results were published in the journal Science.
Billed as the fastest computers of the future, expectations for quantum computers are correspondingly high. But there are still a number of hurdles to overcome before they can be realized. One of these challenges is the fragility of the quantum bits, or qubits for short. Until now, the various perturbations could only be eliminated with great effort. A team from the two JARA partners Forschungszentrum Jülich and RWTH Aachen University, led by JARA professor David DiVincenzo, has now presented a design for a circuit with passive error correction that would simplify the construction of quantum computers.
For several years now, JARA-BRAIN and JARA-SOFT scientist Prof. Dieter Willbold and his team have been researching Alzheimer's disease. With the drug candidate PRI-002, the biochemist developed a potential Alzheimer's drug that has now entered the next important phase of testing. The agent can now be tested in Alzheimer's patients as part of a Phase II clinical trial, following a Phase I clinical trial in early 2019 that already demonstrated its safety and tolerability when used daily in humans for four weeks.